Trial reportScientific reports2026
Peripheral miRNA profiling identifies therapy-specific biological trajectories in the treatment of cognitive dysfunction in depression: an exploratory mechanistic study.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive dysfunction in major depressive disorder (MDD) often persists despite standard treatment. Integral cognitive remediation (INCREM) shows clinical efficacy, yet its molecular drivers remain poorly understood compared to supportive interventions like psychoeducation (PSYCHOED). In this exploratory study, we investigated whether circulating microRNAs (miRNAs) reflect the distinct biological trajectories of these interventions. We conducted a longitudinal analysis of 38 candidate miRNAs (previously validated in postmortem brain tissue of MDD individuals) in plasma from 22 patients with MDD participating in a randomized clinical trial who were assigned to 12 weeks of INCREM or PSYCHOED. Using bioinformatic pathway analyses (KEGG/GO), we identified non-overlapping miRNA profiles associated with each treatment. The INCREM response was characterized by a specific seven-miRNA signature (let-7b-3p, miR-100-5p, miR-129-5p, miR-135a-5p, miR-151a-5p, miR-4516, and miR-451a) targeting gene networks regulated in neuroplasticity, axon guidance, and synaptic transmission. These molecular changes mirrored significant objective cognitive improvements. Conversely, PSYCHOED induced a distinct profile (miR-126-5p and miR-195-5p) related to systemic cellular homeostasis and Wnt signaling, without objective cognitive gains. Our findings suggest that psychological therapies act as specific biological stimuli with distinct molecular targets. These circulating miRNA signatures provide preliminary evidence of neuroplasticity-related pathways as key drivers of cognitive recovery, offering potential blood-based biomarkers for precision psychiatry in MDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.